Replies to post #16734 on The Rising Influence of Rising Affluence

[DewDiligence]

LLY to IPO ~$20% of animal-health biz:

https://www.prnewswire.com/news-releases/lilly-to-separate-elanco-animal-health-with-initial-public-offering-300685125.html

LLY’s animal-health business, called Elanco, logged 13% of LLY’s overall sales in 2017.

[DewDiligence]

MRK’s 2Q18 companion-animal sales increased 19% YoY; 60% of MRK’s 2Q18 overall sales were ex-US:

https://finance.yahoo.com/news/merck-announces-second-quarter-2018-104500377.html

[DewDiligence]

MRK/Eisai's Lenvima approved in China for treatment of hepatocellular carcinoma (liver cancer):

https://finance.yahoo.com/news/eisai-merck-announce-china-national-104500897.html

[DewDiligence]

China approving Western drugs at increasing pace—CFDA review of MRK’s Gardasil took only 9 days(!):

https://www.wsj.com/articles/china-opens-door-to-foreign-drugs-for-a-discount-1543320003

[DewDiligence]

MRK claims to have fastest growth rate in China of any large multinational company; this includes the company’s animal-health unit as well as (human) pharmaceuticals.

Source: Today’s MRK Investor Day webcast.

PR:
https://s21.q4cdn.com/488056881/files/doc_events/2019/Investor_Day/Merck-News-Release-06-20-19-Merck-Hosts-2019-Investor-Day-Outlining-Business-Momentum-Strong-Expected-Growth-and-Focus-on-Innovative-R-D.pdf

CC slides:
https://s21.q4cdn.com/488056881/files/doc_downloads/2019/06/Investor-Day-Presentation.pdf

[DewDiligence]

MRK acquires pet-parasiticide line from VIRP.PA for $400M:

https://www.businesswire.com/news/home/20200512005998/en

Drugs and vaccines for pets are a key growth driver for MRK (#msg-141323511).